CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells

Rene Opavsky, Shu Huei Wang, Prashant Trikha, Aparna Raval, Yuan Huang, Yue Zhong Wu, Benjamin Rodriguez, Benjamin Keller, Sandya Liyanarachchi, Guo Wei, Ramana V. Davuluri, Michael Weinstein, Dean Felsher, Michael Ostrowski, Gustavo Leone, Christoph Plass

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Hypermethylation of CpG islands is a common epigenetic alteration associated with cancer. Global patterns of hypermethylation are tumor-type specific and nonrandom. The biological significance and the underlying mechanisms of tumor-specific aberrant promoter methylation remain unclear, but some evidence suggests that this specificity involves differential sequence susceptibilities, the targeting of DNA methylation activity to specific promoter sequences, or the selection of rare DNA methylation events during disease progression. Using restriction landmark genomic scanning on samples derived from tissue culture and in vivo models of T cell lymphomas, we found that MYC overexpression gave rise to a specific signature of CpG island hypermethylation. This signature reflected gene transcription profiles and was detected only in advanced stages of disease. The further inactivation of the Pten, p53, and E2f2 tumor suppressors in MYC-induced lymphomas resulted in distinct and diagnostic CpG island methylation signatures. Our data suggest that tumor-specific DNA methylation in lymphomas arises as a result of the selection of rare DNA methylation events during the course of tumor development. This selection appears to be driven by the genetic configuration of tumor cells, providing experimental evidence for a causal role of DNA hypermethylation in tumor progression and an explanation for the tremendous epigenetic heterogeneity observed in the evolution of human cancers. The ability to predict genome-wide epigenetic silencing based on relatively few genetic alterations will allow for a more complete classification of tumors and understanding of tumor cell biology.

Original languageEnglish (US)
Pages (from-to)1757-1769
Number of pages13
JournalPLoS genetics
Volume3
Issue number9
DOIs
StatePublished - Sep 1 2007

Fingerprint

CpG Islands
methylation
lymphoma
tumor
Methylation
Lymphoma
animal models
neoplasms
DNA methylation
Neoplasms
DNA Methylation
DNA
epigenetics
Epigenomics
cancer
promoter regions
neoplasm cells
disease course
cell biology
T-Cell Lymphoma

ASJC Scopus subject areas

  • Ecology, Evolution, Behavior and Systematics
  • Molecular Biology
  • Genetics
  • Genetics(clinical)
  • Cancer Research

Cite this

Opavsky, R., Wang, S. H., Trikha, P., Raval, A., Huang, Y., Wu, Y. Z., ... Plass, C. (2007). CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. PLoS genetics, 3(9), 1757-1769. https://doi.org/10.1371/journal.pgen.0030167

CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. / Opavsky, Rene; Wang, Shu Huei; Trikha, Prashant; Raval, Aparna; Huang, Yuan; Wu, Yue Zhong; Rodriguez, Benjamin; Keller, Benjamin; Liyanarachchi, Sandya; Wei, Guo; Davuluri, Ramana V.; Weinstein, Michael; Felsher, Dean; Ostrowski, Michael; Leone, Gustavo; Plass, Christoph.

In: PLoS genetics, Vol. 3, No. 9, 01.09.2007, p. 1757-1769.

Research output: Contribution to journalArticle

Opavsky, R, Wang, SH, Trikha, P, Raval, A, Huang, Y, Wu, YZ, Rodriguez, B, Keller, B, Liyanarachchi, S, Wei, G, Davuluri, RV, Weinstein, M, Felsher, D, Ostrowski, M, Leone, G & Plass, C 2007, 'CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells', PLoS genetics, vol. 3, no. 9, pp. 1757-1769. https://doi.org/10.1371/journal.pgen.0030167
Opavsky, Rene ; Wang, Shu Huei ; Trikha, Prashant ; Raval, Aparna ; Huang, Yuan ; Wu, Yue Zhong ; Rodriguez, Benjamin ; Keller, Benjamin ; Liyanarachchi, Sandya ; Wei, Guo ; Davuluri, Ramana V. ; Weinstein, Michael ; Felsher, Dean ; Ostrowski, Michael ; Leone, Gustavo ; Plass, Christoph. / CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells. In: PLoS genetics. 2007 ; Vol. 3, No. 9. pp. 1757-1769.
@article{60e5aa68b1ab4eaa9509db8afe0d5f2c,
title = "CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells",
abstract = "Hypermethylation of CpG islands is a common epigenetic alteration associated with cancer. Global patterns of hypermethylation are tumor-type specific and nonrandom. The biological significance and the underlying mechanisms of tumor-specific aberrant promoter methylation remain unclear, but some evidence suggests that this specificity involves differential sequence susceptibilities, the targeting of DNA methylation activity to specific promoter sequences, or the selection of rare DNA methylation events during disease progression. Using restriction landmark genomic scanning on samples derived from tissue culture and in vivo models of T cell lymphomas, we found that MYC overexpression gave rise to a specific signature of CpG island hypermethylation. This signature reflected gene transcription profiles and was detected only in advanced stages of disease. The further inactivation of the Pten, p53, and E2f2 tumor suppressors in MYC-induced lymphomas resulted in distinct and diagnostic CpG island methylation signatures. Our data suggest that tumor-specific DNA methylation in lymphomas arises as a result of the selection of rare DNA methylation events during the course of tumor development. This selection appears to be driven by the genetic configuration of tumor cells, providing experimental evidence for a causal role of DNA hypermethylation in tumor progression and an explanation for the tremendous epigenetic heterogeneity observed in the evolution of human cancers. The ability to predict genome-wide epigenetic silencing based on relatively few genetic alterations will allow for a more complete classification of tumors and understanding of tumor cell biology.",
author = "Rene Opavsky and Wang, {Shu Huei} and Prashant Trikha and Aparna Raval and Yuan Huang and Wu, {Yue Zhong} and Benjamin Rodriguez and Benjamin Keller and Sandya Liyanarachchi and Guo Wei and Davuluri, {Ramana V.} and Michael Weinstein and Dean Felsher and Michael Ostrowski and Gustavo Leone and Christoph Plass",
year = "2007",
month = "9",
day = "1",
doi = "10.1371/journal.pgen.0030167",
language = "English (US)",
volume = "3",
pages = "1757--1769",
journal = "PLoS Genetics",
issn = "1553-7390",
publisher = "Public Library of Science",
number = "9",

}

TY - JOUR

T1 - CpG island methylation in a mouse model of lymphoma is driven by the genetic configuration of tumor cells

AU - Opavsky, Rene

AU - Wang, Shu Huei

AU - Trikha, Prashant

AU - Raval, Aparna

AU - Huang, Yuan

AU - Wu, Yue Zhong

AU - Rodriguez, Benjamin

AU - Keller, Benjamin

AU - Liyanarachchi, Sandya

AU - Wei, Guo

AU - Davuluri, Ramana V.

AU - Weinstein, Michael

AU - Felsher, Dean

AU - Ostrowski, Michael

AU - Leone, Gustavo

AU - Plass, Christoph

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Hypermethylation of CpG islands is a common epigenetic alteration associated with cancer. Global patterns of hypermethylation are tumor-type specific and nonrandom. The biological significance and the underlying mechanisms of tumor-specific aberrant promoter methylation remain unclear, but some evidence suggests that this specificity involves differential sequence susceptibilities, the targeting of DNA methylation activity to specific promoter sequences, or the selection of rare DNA methylation events during disease progression. Using restriction landmark genomic scanning on samples derived from tissue culture and in vivo models of T cell lymphomas, we found that MYC overexpression gave rise to a specific signature of CpG island hypermethylation. This signature reflected gene transcription profiles and was detected only in advanced stages of disease. The further inactivation of the Pten, p53, and E2f2 tumor suppressors in MYC-induced lymphomas resulted in distinct and diagnostic CpG island methylation signatures. Our data suggest that tumor-specific DNA methylation in lymphomas arises as a result of the selection of rare DNA methylation events during the course of tumor development. This selection appears to be driven by the genetic configuration of tumor cells, providing experimental evidence for a causal role of DNA hypermethylation in tumor progression and an explanation for the tremendous epigenetic heterogeneity observed in the evolution of human cancers. The ability to predict genome-wide epigenetic silencing based on relatively few genetic alterations will allow for a more complete classification of tumors and understanding of tumor cell biology.

AB - Hypermethylation of CpG islands is a common epigenetic alteration associated with cancer. Global patterns of hypermethylation are tumor-type specific and nonrandom. The biological significance and the underlying mechanisms of tumor-specific aberrant promoter methylation remain unclear, but some evidence suggests that this specificity involves differential sequence susceptibilities, the targeting of DNA methylation activity to specific promoter sequences, or the selection of rare DNA methylation events during disease progression. Using restriction landmark genomic scanning on samples derived from tissue culture and in vivo models of T cell lymphomas, we found that MYC overexpression gave rise to a specific signature of CpG island hypermethylation. This signature reflected gene transcription profiles and was detected only in advanced stages of disease. The further inactivation of the Pten, p53, and E2f2 tumor suppressors in MYC-induced lymphomas resulted in distinct and diagnostic CpG island methylation signatures. Our data suggest that tumor-specific DNA methylation in lymphomas arises as a result of the selection of rare DNA methylation events during the course of tumor development. This selection appears to be driven by the genetic configuration of tumor cells, providing experimental evidence for a causal role of DNA hypermethylation in tumor progression and an explanation for the tremendous epigenetic heterogeneity observed in the evolution of human cancers. The ability to predict genome-wide epigenetic silencing based on relatively few genetic alterations will allow for a more complete classification of tumors and understanding of tumor cell biology.

UR - http://www.scopus.com/inward/record.url?scp=34848812553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848812553&partnerID=8YFLogxK

U2 - 10.1371/journal.pgen.0030167

DO - 10.1371/journal.pgen.0030167

M3 - Article

VL - 3

SP - 1757

EP - 1769

JO - PLoS Genetics

JF - PLoS Genetics

SN - 1553-7390

IS - 9

ER -